Mylan N.V. (NASDAQ:MYL) will be issuing its quarterly earnings data before the market opens on Monday, November 6th. Analysts expect the company to announce earnings of $1.20 per share for the quarter. Mylan N.V. has set its FY17 guidance at $4.30-4.70 EPS.
Mylan N.V. (NASDAQ:MYL) last released its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. During the same quarter in the previous year, the business earned $1.16 EPS. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. On average, analysts expect Mylan N.V. to post $4.63 EPS for the current fiscal year and $5.29 EPS for the next fiscal year.
Mylan N.V. (MYL) traded down 0.37% during mid-day trading on Monday, reaching $38.21. The company’s stock had a trading volume of 475,832 shares. The firm’s 50 day moving average price is $35.12 and its 200 day moving average price is $36.26. The stock has a market cap of $20.49 billion, a price-to-earnings ratio of 30.89 and a beta of 1.30. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87.
Several equities analysts have recently commented on the company. Citigroup Inc. set a $42.00 price target on Mylan N.V. and gave the company a “buy” rating in a research note on Wednesday, October 4th. Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. UBS AG reiterated a “buy” rating and issued a $46.00 price objective (down previously from $50.00) on shares of Mylan N.V. in a report on Thursday, August 10th. BidaskClub upgraded Mylan N.V. from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th. Finally, Instinet reiterated a “buy” rating and issued a $37.00 price objective on shares of Mylan N.V. in a report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $41.21.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.